Infectious Diseases

The HIV-Coinfected
Patient: Managing
Viral Hepatitis

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Infectious Diseases.

The HIV-Coinfected Patient: Managing Viral Hepatitis

Order Journal Supplement

Get your FREE copy of this outstanding report on HIV/HBV and HIV/HCV coinfection and cirrhosis!

The scholarly reviews in this journal supplement focus on the knowledge and skills clinicians need to treat liver disease and viral hepatitis—hepatitis B virus (HBV) and/or hepatitis C virus (HCV)—in persons with HIV infection. Disease epidemiology, natural history, the diagnosis and management of coinfected patients, and the multifaceted approach to addressing the complications associated with cirrhosis are presented.

Don't miss this important and informative journal supplement, and earn up to 3.0 AMA PRA Category 1 Credits^TM. Order your free copy today!

Guest Editor
Mark S. Sulkowski, MD Associate Professor of Medicine, Division of Infectious Diseases Department of Medicine, Johns Hopkins University School of Medicine Baltimore, MD
Contributors Yves Benhamou, MD Praticien Hospitalier Service d'Hépato-Gastro-Entérologie Groupe Hôspitalier Pitié-Salpêtrière Paris, France
Maurizio Bonacini, MD Associate Clinical Professor, University of California at San Francisco Director, HIV-Liver Program Department of Transplantation California Pacific Medical Center San Francisco, CA
Barbara H. McGovern, MD Director, HIV/Hepatitis C Coinfection Center Division of Infectious Diseases, Lemuel Shattuck Hospital Jamaica Plain, MA Assistant Professor of Medicine, Tufts University School of Medicine Boston, MA

top

TARGET AUDIENCE

This activity is designed for infectious disease specialists who care for HIV-infected patients who are also infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV).

LEARNING OBJECTIVES

Based on the latest epidemiologic and diagnostic information, detect and monitor comorbid hepatitis/HIV to ensure early intervention and improve patient outcomes.
Assess status/stage of liver disease in HIV-coinfected patients to determine intervention treatment strategy, drawing on current information specific to hepatitis disease progression in HIV-coinfected patients.
Formulate customized treatment regimens for HIV patients coinfected with viral hepatitis for improved outcomes by assessing the patient's health status and integrating knowledge of antiviral and antiretroviral therapies.
Monitor therapeutic response and adverse effects of therapy in HIV-coinfected patients, and implement management strategies for adverse effects that improve patient outcomes.

top

CME INFORMATION

STATEMENT OF ACCREDITATION

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Projects In Knowledge designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME INSTRUCTIONS

To receive CME credit for your participation in this activity:

Please read this supplement carefully.
Complete/submit the posttest and evaluation.
Instantly access and print out your certificate.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

PILOT TEST ACKNOWLEDGEMENT

Projects In Knowledge thanks Ira S. Goldman, MD, Manhasset, NY, for pilot testing this activity.

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Yves Benhamou, MD, is a consultant for and is on the speakers bureau and advisory boards of Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals Inc, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated.

Maurizio Bonacini, MD, has received grant/research support from Ortho Biotech Products, LP, and Roche Pharmaceuticals, and is on the speakers bureau for Bristol-Myers Squibb and Roche Pharmaceuticals. Dr. Bonacini will not discuss unlabeled/unapproved drugs or products.

Barbara H. McGovern, MD, is a consultant for and is on the speakers bureau of Roche Pharmaceuticals. Dr. McGovern has disclosed that she will reference unlabeled/unapproved use of pegylated interferon in maintenance therapy, epoetin alfa, and filgrastim.

Mark S. Sulkowski, MD, has received grant/research support from Bristol-Myers Squibb, Human Genome Sciences, Idenix Pharmaceuticals, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals International; is on the speakers bureau for Roche Pharmaceuticals and Schering-Plough Corporation; and is on the scientific advisory boards of Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Human Genome Sciences, Ortho Biotech Products, LP, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals International. Dr. Sulkowski will not discuss unlabeled/unapproved drugs or products.

Peer Reviewer has no significant relationships to disclose.

JAIDS Peer Reviewer

Paul A. Volberding, MD, is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Schering-Plough Corporation.

Projects In Knowledge's staff members have disclosed no significant relationships.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge and are resolved prior to the beginning of the activity.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME activity is supported by an educational grant from Bristol-Myers Squibb.

top

1750